Novartis Deal, AI, and Biotech Shifts
Kilder
- Endpoints: Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
- Fierce Biotech: Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager - Fierce Biotech
- Pharmtech: ABO2203's $7.2B Milestones Signal RNA Capacity Demand - PharmTech.com
- Finance: Novartis pays $575 million upfront for Abogen's mRNA autoimmune therapy in deal worth up to $7.8 billion - finance.biggo.com
- Labiotech: How Flagship’s Valo is reshaping AI drug discovery with human data
- Finance: Valo's Brian Alexander: AI Won't Fix Drug Discovery Until Human Biology Moves Upstream - finance.biggo.com
- Endpoints: Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
- BioPharma Dive: This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
- Endpoints: Geographic atrophy biotech Aviceda to shut down after Phase 2 fail
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.